Status:
ACTIVE_NOT_RECRUITING
Identification of New Biomarkers of Insulin Resistance
Lead Sponsor:
University of Bath
Collaborating Sponsors:
Teagasc
Conditions:
Insulin Resistance
Diabetes Mellitus, Type 2
Eligibility:
All Genders
40-65 years
Phase:
NA
Brief Summary
Diabetes is a chronic metabolic disease affecting 415 million people worldwide, 90% of cases are type 2 which is frequently associated with obesity and a sedentary lifestyle. In healthy individuals, i...
Detailed Description
Diabetes is a chronic metabolic disease affecting 415 million people worldwide and 3.5 million people in the UK, with ninety percent suffering from type 2 diabetes. Type 2 diabetes is characterised by...
Eligibility Criteria
Inclusion
- Male or female
- Age 40-65
- BMI ≥25 to ≤ 40 kg/m2
- Physical activity level \<1.75 (daily average)
- Waist size \>80 cm (female) or \>94 cm (male)
- Weight stable for \>3 months
Exclusion
- Inability to undertake exercise as determined by PAR-Q
- Diagnosed diabetes
- Ongoing or planned lifestyle changes (diet/exercise)
- Recent large shift in bodyweight (\>2.5%) within the last 3 months?
- Smoker (or having ceased \<6mo ago)
- Metabolic disorders
- Hypertension defined as \>160/100
- Use of anti-inflammatory medication: NSAIDs
- Cardiovascular disease
- Any bleeding disorder or taking anticoagulant medication
- Use of antibiotics within the last three months
- Use of pro/pre-biotics within one month of first trial day.
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03362554
Start Date
February 1 2018
End Date
January 1 2028
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department for Health, University of Bath
Bath, United Kingdom, BA2 7AY